Selected research
Industry Research
Biosimulation Software Industry Research Report 2026
Market perspective
The global Biosimulation Software market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Biosimulation Software market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Biosimulation Software market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Biosimulation Software market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Biosimulation Software include Certara, Simulations, Dassault Systèmes, Schrödinger, Advanced Chemistry, Chemical Computing, Rosa & Co., Genedata and Physiomics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Biosimulation Software market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Biosimulation Software.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biosimulation Software Market by Company
Certara
Simulations
Dassault Systèmes
Schrödinger
Advanced Chemistry
Chemical Computing
Rosa & Co.
Genedata
Physiomics
In Silico Biosciences
Allucent
OpenEye (Cadence)
Cellworks Group
VeriSIM Life
Netabolics SRL
Charnwood Discovery
The MathWorks
ANSYS
Instem Group of Companies
Insilico Medicine
SCM
BioSymetrics
Atomwise
insitro
Clinithink
Biosimulation Software Segment by Type
Independent Modules
Integrated Software Platform
Biosimulation Software Segment by Application
Pharmaceuticals
Medical Research
Others
Biosimulation Software Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimulation Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimulation Software and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimulation Software.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Biosimulation Software companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Independent Modules
- Integrated Software Platform
Applications
- Pharmaceuticals
- Medical Research
- Others
Companies covered
- Certara
- Simulations
- Dassault Systèmes
- Schrödinger
- Advanced Chemistry
- Chemical Computing
- Rosa & Co.
- Genedata
- Physiomics
- In Silico Biosciences
- Allucent
- OpenEye (Cadence)
- Cellworks Group
- VeriSIM Life
- Netabolics SRL
- Charnwood Discovery
- The MathWorks
- ANSYS
- Instem Group of Companies
- Insilico Medicine
- SCM
- BioSymetrics
- Atomwise
- insitro
- Clinithink
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Biosimulation Software by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Independent Modules
- 2.2.3 Integrated Software Platform
- 2.3 Biosimulation Software by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmaceuticals
- 2.3.3 Medical Research
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Biosimulation Software Breakdown Data by Type
- 3.1 Global Biosimulation Software Historic Market Size by Type (2021-2026)
- 3.2 Global Biosimulation Software Forecasted Market Size by Type (2027-2032)
4 Biosimulation Software Breakdown Data by Application
- 4.1 Global Biosimulation Software Historic Market Size by Application (2021-2026)
- 4.2 Global Biosimulation Software Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Biosimulation Software Market Perspective (2021-2032)
- 5.2 Global Biosimulation Software Growth Trends by Region
- 5.2.1 Global Biosimulation Software Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Biosimulation Software Historic Market Size by Region (2021-2026)
- 5.2.3 Biosimulation Software Forecasted Market Size by Region (2027-2032)
- 5.3 Biosimulation Software Market Dynamics
- 5.3.1 Biosimulation Software Industry Trends
- 5.3.2 Biosimulation Software Market Drivers
- 5.3.3 Biosimulation Software Market Challenges
- 5.3.4 Biosimulation Software Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Biosimulation Software Players by Revenue
- 6.1.1 Global Top Biosimulation Software Players by Revenue (2021-2026)
- 6.1.2 Global Biosimulation Software Revenue Market Share by Players (2021-2026)
- 6.2 Global Biosimulation Software Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Biosimulation Software Head Office and Area Served
- 6.4 Global Biosimulation Software Players, Product Type & Application
- 6.5 Global Biosimulation Software Manufacturers Established Date
- 6.6 Global Biosimulation Software Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Biosimulation Software Market Size (2021-2032)
- 7.2 North America Biosimulation Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Biosimulation Software Market Size by Country (2021-2026)
- 7.4 North America Biosimulation Software Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Biosimulation Software Market Size (2021-2032)
- 8.2 Europe Biosimulation Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Biosimulation Software Market Size by Country (2021-2026)
- 8.4 Europe Biosimulation Software Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Biosimulation Software Market Size (2021-2032)
- 9.2 Asia-Pacific Biosimulation Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Biosimulation Software Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Biosimulation Software Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Biosimulation Software Market Size (2021-2032)
- 10.2 South America Biosimulation Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Biosimulation Software Market Size by Country (2021-2026)
- 10.4 South America Biosimulation Software Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Biosimulation Software Market Size (2021-2032)
- 11.2 Middle East & Africa Biosimulation Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Biosimulation Software Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Biosimulation Software Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Certara
- 12.1.1 Certara Company Information
- 12.1.2 Certara Business Overview
- 12.1.3 Certara Revenue in Biosimulation Software Business (2021-2026)
- 12.1.4 Certara Biosimulation Software Product Portfolio
- 12.1.5 Certara Recent Developments
- 12.2 Simulations
- 12.2.1 Simulations Company Information
- 12.2.2 Simulations Business Overview
- 12.2.3 Simulations Revenue in Biosimulation Software Business (2021-2026)
- 12.2.4 Simulations Biosimulation Software Product Portfolio
- 12.2.5 Simulations Recent Developments
- 12.3 Dassault Systèmes
- 12.3.1 Dassault Systèmes Company Information
- 12.3.2 Dassault Systèmes Business Overview
- 12.3.3 Dassault Systèmes Revenue in Biosimulation Software Business (2021-2026)
- 12.3.4 Dassault Systèmes Biosimulation Software Product Portfolio
- 12.3.5 Dassault Systèmes Recent Developments
- 12.4 Schrödinger
- 12.4.1 Schrödinger Company Information
- 12.4.2 Schrödinger Business Overview
- 12.4.3 Schrödinger Revenue in Biosimulation Software Business (2021-2026)
- 12.4.4 Schrödinger Biosimulation Software Product Portfolio
- 12.4.5 Schrödinger Recent Developments
- 12.5 Advanced Chemistry
- 12.5.1 Advanced Chemistry Company Information
- 12.5.2 Advanced Chemistry Business Overview
- 12.5.3 Advanced Chemistry Revenue in Biosimulation Software Business (2021-2026)
- 12.5.4 Advanced Chemistry Biosimulation Software Product Portfolio
- 12.5.5 Advanced Chemistry Recent Developments
- 12.6 Chemical Computing
- 12.6.1 Chemical Computing Company Information
- 12.6.2 Chemical Computing Business Overview
- 12.6.3 Chemical Computing Revenue in Biosimulation Software Business (2021-2026)
- 12.6.4 Chemical Computing Biosimulation Software Product Portfolio
- 12.6.5 Chemical Computing Recent Developments
- 12.7 Rosa & Co.
- 12.7.1 Rosa & Co. Company Information
- 12.7.2 Rosa & Co. Business Overview
- 12.7.3 Rosa & Co. Revenue in Biosimulation Software Business (2021-2026)
- 12.7.4 Rosa & Co. Biosimulation Software Product Portfolio
- 12.7.5 Rosa & Co. Recent Developments
- 12.8 Genedata
- 12.8.1 Genedata Company Information
- 12.8.2 Genedata Business Overview
- 12.8.3 Genedata Revenue in Biosimulation Software Business (2021-2026)
- 12.8.4 Genedata Biosimulation Software Product Portfolio
- 12.8.5 Genedata Recent Developments
- 12.9 Physiomics
- 12.9.1 Physiomics Company Information
- 12.9.2 Physiomics Business Overview
- 12.9.3 Physiomics Revenue in Biosimulation Software Business (2021-2026)
- 12.9.4 Physiomics Biosimulation Software Product Portfolio
- 12.9.5 Physiomics Recent Developments
- 12.10 In Silico Biosciences
- 12.10.1 In Silico Biosciences Company Information
- 12.10.2 In Silico Biosciences Business Overview
- 12.10.3 In Silico Biosciences Revenue in Biosimulation Software Business (2021-2026)
- 12.10.4 In Silico Biosciences Biosimulation Software Product Portfolio
- 12.10.5 In Silico Biosciences Recent Developments
- 12.11 Allucent
- 12.11.1 Allucent Company Information
- 12.11.2 Allucent Business Overview
- 12.11.3 Allucent Revenue in Biosimulation Software Business (2021-2026)
- 12.11.4 Allucent Biosimulation Software Product Portfolio
- 12.11.5 Allucent Recent Developments
- 12.12 OpenEye (Cadence)
- 12.12.1 OpenEye (Cadence) Company Information
- 12.12.2 OpenEye (Cadence) Business Overview
- 12.12.3 OpenEye (Cadence) Revenue in Biosimulation Software Business (2021-2026)
- 12.12.4 OpenEye (Cadence) Biosimulation Software Product Portfolio
- 12.12.5 OpenEye (Cadence) Recent Developments
- 12.13 Cellworks Group
- 12.13.1 Cellworks Group Company Information
- 12.13.2 Cellworks Group Business Overview
- 12.13.3 Cellworks Group Revenue in Biosimulation Software Business (2021-2026)
- 12.13.4 Cellworks Group Biosimulation Software Product Portfolio
- 12.13.5 Cellworks Group Recent Developments
- 12.14 VeriSIM Life
- 12.14.1 VeriSIM Life Company Information
- 12.14.2 VeriSIM Life Business Overview
- 12.14.3 VeriSIM Life Revenue in Biosimulation Software Business (2021-2026)
- 12.14.4 VeriSIM Life Biosimulation Software Product Portfolio
- 12.14.5 VeriSIM Life Recent Developments
- 12.15 Netabolics SRL
- 12.15.1 Netabolics SRL Company Information
- 12.15.2 Netabolics SRL Business Overview
- 12.15.3 Netabolics SRL Revenue in Biosimulation Software Business (2021-2026)
- 12.15.4 Netabolics SRL Biosimulation Software Product Portfolio
- 12.15.5 Netabolics SRL Recent Developments
- 12.16 Charnwood Discovery
- 12.16.1 Charnwood Discovery Company Information
- 12.16.2 Charnwood Discovery Business Overview
- 12.16.3 Charnwood Discovery Revenue in Biosimulation Software Business (2021-2026)
- 12.16.4 Charnwood Discovery Biosimulation Software Product Portfolio
- 12.16.5 Charnwood Discovery Recent Developments
- 12.17 The MathWorks
- 12.17.1 The MathWorks Company Information
- 12.17.2 The MathWorks Business Overview
- 12.17.3 The MathWorks Revenue in Biosimulation Software Business (2021-2026)
- 12.17.4 The MathWorks Biosimulation Software Product Portfolio
- 12.17.5 The MathWorks Recent Developments
- 12.18 ANSYS
- 12.18.1 ANSYS Company Information
- 12.18.2 ANSYS Business Overview
- 12.18.3 ANSYS Revenue in Biosimulation Software Business (2021-2026)
- 12.18.4 ANSYS Biosimulation Software Product Portfolio
- 12.18.5 ANSYS Recent Developments
- 12.19 Instem Group of Companies
- 12.19.1 Instem Group of Companies Company Information
- 12.19.2 Instem Group of Companies Business Overview
- 12.19.3 Instem Group of Companies Revenue in Biosimulation Software Business (2021-2026)
- 12.19.4 Instem Group of Companies Biosimulation Software Product Portfolio
- 12.19.5 Instem Group of Companies Recent Developments
- 12.20 Insilico Medicine
- 12.20.1 Insilico Medicine Company Information
- 12.20.2 Insilico Medicine Business Overview
- 12.20.3 Insilico Medicine Revenue in Biosimulation Software Business (2021-2026)
- 12.20.4 Insilico Medicine Biosimulation Software Product Portfolio
- 12.20.5 Insilico Medicine Recent Developments
- 12.21 SCM
- 12.21.1 SCM Company Information
- 12.21.2 SCM Business Overview
- 12.21.3 SCM Revenue in Biosimulation Software Business (2021-2026)
- 12.21.4 SCM Biosimulation Software Product Portfolio
- 12.21.5 SCM Recent Developments
- 12.22 BioSymetrics
- 12.22.1 BioSymetrics Company Information
- 12.22.2 BioSymetrics Business Overview
- 12.22.3 BioSymetrics Revenue in Biosimulation Software Business (2021-2026)
- 12.22.4 BioSymetrics Biosimulation Software Product Portfolio
- 12.22.5 BioSymetrics Recent Developments
- 12.23 Atomwise
- 12.23.1 Atomwise Company Information
- 12.23.2 Atomwise Business Overview
- 12.23.3 Atomwise Revenue in Biosimulation Software Business (2021-2026)
- 12.23.4 Atomwise Biosimulation Software Product Portfolio
- 12.23.5 Atomwise Recent Developments
- 12.24 insitro
- 12.24.1 insitro Company Information
- 12.24.2 insitro Business Overview
- 12.24.3 insitro Revenue in Biosimulation Software Business (2021-2026)
- 12.24.4 insitro Biosimulation Software Product Portfolio
- 12.24.5 insitro Recent Developments
- 12.25 Clinithink
- 12.25.1 Clinithink Company Information
- 12.25.2 Clinithink Business Overview
- 12.25.3 Clinithink Revenue in Biosimulation Software Business (2021-2026)
- 12.25.4 Clinithink Biosimulation Software Product Portfolio
- 12.25.5 Clinithink Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst